- Home
- RNA vs VIRT Comparison
RNA vs VIRT Comparison
Compare RNA & VIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNA | VIRT |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 2.8B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RNA | VIRT |
|---|---|---|
| Price | $71.76 | $35.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 7 |
| Target Price | ★ $69.26 | $41.43 |
| AVG Volume (30 Days) | ★ 2.9M | 732.9K |
| Earning Date | 11-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | N/A | ★ 132.69 |
| EPS | N/A | ★ 4.62 |
| Revenue | $20,868,000.00 | ★ $2,694,104,000.00 |
| Revenue This Year | $64.11 | N/A |
| Revenue Next Year | $37.25 | N/A |
| P/E Ratio | ★ N/A | $7.67 |
| Revenue Growth | ★ 106.27 | 41.05 |
| 52 Week Low | $21.51 | $31.89 |
| 52 Week High | $71.79 | $45.77 |
Technical Indicators
Market Signals| Indicator | RNA | VIRT |
|---|---|---|
| Relative Strength Index (RSI) | 77.56 | 55.14 |
| Support Level | $71.42 | $34.16 |
| Resistance Level | $71.76 | $35.89 |
| Average True Range (ATR) | 0.41 | 0.85 |
| MACD | -0.73 | 0.08 |
| Stochastic Oscillator | 88.32 | 77.99 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About VIRT Virtu Financial Inc.
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.